WARRENDALE, Pa., Dec. 3 /PRNewswire/ -- Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Connect.PACS(TM) product, enabling the first radiology informatics capabilities of its kind, is the latest release in the company's newly branded Certegra(TM) Informatics Platform.
Certegra products automate and advance how patient and study information is generated, integrated and mobilized within radiology. Certegra products automate record keeping; integrate injection records into PACS; personalize contrast dosing (P3T(TM)); integrate CT scanner and injector operation (ISI); and enable remote equipment service.
"MEDRAD is using informatics to open up access to data providing clinical, research, and operational benefits within an enterprise," says William Boonn, M.D., Chief 3D and Advanced Imaging, Hospital of the University of Pennsylvania. "Clinical records integration offers built-in workflow efficiencies and productivity potential. Without it, radiologists have to either track down the technologist who performed a study or go to the scanner directly to get the information they need."
Certegra's Connect.PACS builds on current platform capabilities including information capture, automated record keeping and compliance documentation, as well as additional reporting options. Connect.PACS immediately transfers a patient's CT contrast-injection record to PACS, eliminating the need to manually enter injection information. The injection record transfer enables radiologists to view injection protocols alongside the patient's PACS image set for real-time and retrospective image analysis.
*Picture Archiving and Communication System
"Demand to deliver improved clinical outcomes while realizing greater cost efficiencies and workflow productivity has never been greater for healthcare providers," says Anthony Cinalli, executive director, MEDRAD Radiology. "We're harnessing the power of informatics to help healthcare professionals meet these needs in ways that, until now, have been largely untapped."
About MEDRAD, Inc.
MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care. More company information is available at www.medrad.com.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For additional information contact: Luanne Radermacher, MEDRAD 724-940-7968 email@example.com
SOURCE MEDRAD, Inc.
|SOURCE MEDRAD, Inc.|
Copyright©2009 PR Newswire.
All rights reserved